Eli Lilly and Company $LLY Shares Sold by LRI Investments LLC

LRI Investments LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,964 shares of the company’s stock after selling 165 shares during the period. LRI Investments LLC’s holdings in Eli Lilly and Company were worth $1,531,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock worth $10,495,261,000 after acquiring an additional 81,587 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after acquiring an additional 682,203 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Eli Lilly and Company in the first quarter worth $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. HSBC boosted their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $833.08 on Monday. The company has a 50-day simple moving average of $742.42 and a 200-day simple moving average of $765.55. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. The business’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.